Company: INKT
Filing Date: 2025-07-15
Form Type: 424B5
Source: 0001193125-25-159014
Chunk: 16

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-07-15
Form: 424B5
Chunk 16
---
 specifically been incorporated by reference in this prospectus
supplement and the accompanying prospectus.

S-14

PROSPECTUS MiNK Therapeutics, Inc. $50,000,000 Common Stock Preferred Stock Warrants Debt Securities Units We may offer to the public from time to time in one or more series or issuances:

| • |     | common stock; |

| • |     | preferred stock; |

| • |     | warrants to purchase our common stock, preferred stock or debt securities; |

| • |     | debt securities consisting of debentures, notes or other evidences of indebtedness; |

| • |     | units consisting of a combination of the foregoing securities; or |

| • |     | any combination of these securities. |

The aggregate initial offering price of all securities sold by us pursuant to this prospectus will not exceed $50,000,000. This prospectus provides a general description of the securities that we may offer. Each time that we offer securities under this prospectus, we will provide the specific terms of the securities offered, including the public offering price, in a supplement to this prospectus. Any prospectus supplement may add to, update or change information contained in this prospectus. You should carefully read this prospectus as well as the documents incorporated or deemed to be incorporated by reference in this prospectus before you purchase any of the securities offered hereby. The securities may be sold by us to or through underwriters or dealers, directly to purchasers or through agents designated from time to time. For additional information on the methods of sale, you should refer to the section entitled “Plan of Distribution” in this prospectus and the comparable section of any applicable prospectus supplement. If any underwriters are involved in the sale of the securities with respect to which this prospectus is being delivered, the names of such underwriters and any applicable discounts or commissions and over-allotment options will be set forth in the applicable prospectus supplement. Our common stock is traded on the Nasdaq Capital Market under the symbol “INKT.” On November 2, 2022, the closing price of our common stock was $2.13. We have not yet determined whether the other securities that may be offered by this prospectus will be listed on any exchange, interdealer quotation system or over-the-countermarket. If we decide to seek the listing of any such securities upon issuance, the prospectus supplement relating to those securities will disclose the exchange, quotation system or market on which those securities will be listed